Jen Saunders

Head of Investor Relations

Equibles does not estimate personal net worth.

Get an email with a short summary when Iovance Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get IOVA alerts

About Jen Saunders

Jen Saunders is recorded as Head of Investor Relations at Iovance Biotherapeutics, Inc. (IOVA). Jen Saunders has spoken on 1 earnings call across 1 company, most recently for Iovance Biotherapeutics, Inc. on November 5, 2026. Iovance Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Iovance Biotherapeutics, Inc. includes Frederick G. Vogt, Ph.D. (CEO), Frederick Vogt (CEO and General Counsel), Corleen Roche (CFO) and 7 others.

Jen Saunders on recent calls

“Good morning, and welcome to the Iovance webcast to discuss our third quarter 2026 financial results, business achievements, and corporate updates.”

Head of Investor Relations, Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 · November 5, 2026

Affiliation history

Iovance Biotherapeutics, Inc. (IOVA)
Head of Investor Relations

Transcript header (unverified)

Current

Company network

Iovance Biotherapeutics, Inc.

IOVA

Current role

Biotechnology · Healthcare

Head of Investor Relations

1 appearance Latest appearance 2026-11-05

View calls and events

Leadership on record at Iovance Biotherapeutics, Inc.

Frederick G. Vogt, Ph.D. CEO
Frederick Vogt CEO, General Counsel
Corleen Roche CFO
Jean-Marc Bellemin CFO
Igor Bilinsky COO
Igor Bilinsky, Ph.D. COO
Matthew W. Rosinack Chief Accounting Officer
Michael C. Swartzburg Chief Accounting Officer
Athena Countouriotis Board Member
Iain Dukes Board Member

Recent activity

Earnings call Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 Iovance Biotherapeutics, Inc. (IOVA)
2026-11-05